BioWorld

Jan. 28, 2009

CVT Rejects $1B Acquisition Offer from Partner Astellas

Astellas Pharma Inc. revealed Tuesday that it has spent the last year attempting to acquire CV Therapeutics Inc., but the biotech rejected its latest $1 billion offer and declined to engage in further discussions. (BioWorld Today) Read More

Theravance Files Telavancin NDA for Hospital-Acquired Pneumonia

Obama Election Called End of 'Sad Chapter' for Science

Mixed Bag of Pipeline News for Amgen as Earnings Fall Short

Drugmakers Slow to Personalized Medicine Risk Market Share

UK Report on Start-ups Calls for New Source of Funding

NitroMed Agrees to Deerfield Sale, but also Vows to Shop Around

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...